英国生物银行队列中MASLD与肝外多病共存及全因死亡的关系
该研究基于英国生物银行438840名参与者,评估MASLD(脂肪肝指数≥60且存在心血管代谢危险因素)与肝外多病共存及全因死亡的关系。MASLD患者多病共存患病率高于非MASLD者(21.3% vs 14.4%),中位随访13年期间MASLD与全因死亡风险升高相关(HR 1.16;95% CI 1.13, 1.19)。
要点
- MASLD患者基线多病共存患病率高于非MASLD者(21.3% vs 14.4%)。
- 中位随访13年,MASLD与全因死亡风险升高相关(HR 1.16;95% CI 1.13, 1.19)。
- 基线每增加一种长期病症,MASLD人群死亡风险升高30%,非MASLD人群升高38%。
核心结论
- MASLD患者肝外多病共存患病率更高,全因死亡率较非MASLD者高16%,强调肝脂肪变性对死亡的影响及针对长期病症以改善结局和减轻医疗负担的必要性。
研究设计与样本
- 基于英国生物银行队列的分析,纳入438840名参与者,MASLD定义为脂肪肝指数≥60且存在心血管代谢危险因素,多病共存定义为47种预设肝外长期病症中≥2种。
- 采用校正Cox模型计算风险比(HR)量化MASLD、多病共存与全因死亡的关联。
主要发现
- 基线时131020名(29.9%)参与者有MASLD,MASLD患者多病共存患病率高于非MASLD者(21.3% vs 14.4%)。
- 中位随访13年,MASLD与全因死亡风险升高相关(HR 1.16;95% CI 1.13, 1.19),在女性和长期病症数≤3的人群中关联更强。
- 基线每增加一种长期病症,MASLD人群死亡风险升高30%(HR 1.30;95% CI 1.29, 1.32),非MASLD人群升高38%(HR 1.38;95% CI 1.37, 1.40)。
- 47种长期病症中,16种与MASLD患者死亡风险增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one third of the world's population, but its associations with extrahepatic multimorbidity and mortality remain unclear. OBJECTIVE: This study aimed to estimate the impact of MASLD, with and without multimorbidity, on all-cause mortality. METHODS: We analyzed data from the UK Biobank. MASLD was identified as a fatty liver index ≥60 and presence of cardiometabolic risk factors. Multimorbidity was defined as ≥2 of the long-term conditions (LTCs) in a prespecified list of 47 extrahepatic conditions. Hazard ratios (HRs) from adjusted Cox models quantified the association between MASLD, multimorbidity and all-cause mortality. RESULTS: Of the 438 840 participants, 131 020 (29.9%) had MASLD at baseline. The participants with MASLD at baseline had a higher prevalence of multimorbidity than those without (21.3% vs 14.4%). In addition to cardiometabolic risk factors, MASLD was strongly associated with several LTCs, particularly metabolic, cardiovascular, cancers, kidney, mental/behavioral, and respiratory diseases. During a median follow-up of 13 years, MASLD was associated with higher mortality (HR 1.16; 95% CI 1.13, 1.19), with stronger associations in females and in those with low LTC counts (≤3 LTCs). Each additional LTC at baseline was associated with 30% and 38% higher mortality in MASLD (HR 1.30; 1.29, 1.32) and non-MASLD (HR 1.38; 1.37, 1.40) populations, respectively. Among the 47 LTCs, 16 were associated with increased mortality in people with MASLD. CONCLUSION: Those with MASLD exhibited a higher prevalence of extrahepatic multimorbidity and a 16% higher rate of mortality than those without, underscoring the impact of liver steatosis on mortality and highlighting the need to target LTCs to improve outcomes and reduce health care burdens.
引用
- Feng Q, Izzi-Engbeaya CN, Branch AD, et al. The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort. J Clin Endocrinol Metab. 2025. PMID: 40493745. doi:10.1210/clinem/dgaf342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。